merck pharma drug-pricing keytruda vaccines ira medicare-negotiation
related: PhRMA Pfizer Eli Lilly AbbVie
Who They Are
Merck & Co., Inc. One of the largest pharmaceutical companies in the world ($64 billion revenue, 2024), headquartered in Rahway, New Jersey. Merck’s blockbuster product is Keytruda — the world’s best-selling drug ($25 billion in 2024 sales), an immunotherapy cancer treatment used across multiple cancer types. Merck PAC contributes $2-3 million per cycle, with lobbying spending of $11-14 million annually.
Merck was the first pharmaceutical company to sue the federal government over the Inflation Reduction Act’s Medicare drug price negotiation provision (June 2023), arguing that compelled negotiation constitutes an unconstitutional “taking” of intellectual property. The lawsuit — ultimately unsuccessful — revealed the pharmaceutical industry’s strategy: using the courts to block legislative wins that survived the lobbying process.
What They Want
Opposition to Medicare drug price negotiation expansion (particularly before Keytruda’s patent expiration), extended patent exclusivity for biologics, favorable FDA approval timelines, reduced importation of drugs from Canada, and opposition to march-in rights (government authority to override patents on federally funded drugs).
What They’ve Gotten
IRA Lawsuit (Failed): Merck’s constitutional challenge to Medicare drug price negotiation was rejected by federal courts, establishing that the government can negotiate prices for Medicare Part D drugs. The litigation strategy — delay implementation through legal challenges — succeeded in slowing the program’s rollout even though the underlying challenge failed.
Keytruda Patent Extension Strategy: Merck has filed 160+ patents on Keytruda and its uses — building a patent thicket designed to extend market exclusivity beyond the original biologic patent expiration. This strategy mirrors AbbVie’s Humira patent thicket and is designed to prevent biosimilar competition that would reduce Keytruda’s $25 billion annual revenue.
Money
Merck’s $11-14 million annual lobbying investment protects Keytruda’s $25 billion annual revenue — a drug that received significant development support from NIH-funded research. The company’s IRA lawsuit attempted to block the government from negotiating the price of a drug partially developed with taxpayer money. Merck’s 160+ Keytruda patents are designed to extend monopoly pricing beyond the original exclusivity period — potentially preserving $25 billion/year in revenue for additional years. The lobbying and litigation costs: approximately $15-20 million annually. The protected revenue: $25 billion annually. The investment-to-return ratio: approximately 1:1,250.
Sources
- OpenSecrets: Merck organizational profile (Tier 1)
- SEC: Merck 10-K filing, Keytruda revenue (Tier 1)
- Ballotpedia: Merck (Tier 3)
content-readiness:: ready